Barclays maintains Elanco Animal Health at Overweight, raises price target to $32 from $30
Barclays has reiterated its 'Overweight' rating for Elanco Animal Health and increased its price target from $30 to $32, representing a 6.7% rise. This new target suggests an upside of 19.9% from the stock's closing price of $26.70 on November 18. Recent analyst actions on Elanco show price targets ranging from $24 to $35 over the past 30 days.
Elanco Authorizes $600 Million Buyback After Leverage Falls Below 3X
Elanco Animal Health (ELAN) has authorized its first share repurchase program, committing up to $600 million for common stock buybacks. This decision follows the company's success in reducing net leverage below 3.0 times adjusted EBITDA, achieving this milestone earlier than anticipated. The buyback program is part of an updated capital-allocation framework that also prioritizes continued debt reduction, accretive growth opportunities, and investment in innovation.
Elanco authorizes $600 million share buyback program
Elanco Animal Health Incorporated announced a $600 million share buyback program, authorized by its Board of Directors. This move follows the company's quicker-than-anticipated achievement of a net leverage ratio below 3.0 times, alongside a continued focus on debt reduction and growth opportunities. Elanco aims for mid-single digit revenue growth, high single digit adjusted EBITDA growth, and low double digit adjusted EPS growth over multiple years.
Elanco Announces Inaugural $600 Million Share Repurchase Authorization
Elanco Animal Health Incorporated has announced its first-ever share repurchase program, authorizing the buyback of up to $600 million of its common stock. This decision reflects the company's strong financial performance, including robust free cash flow generation and successful debt reduction, having lowered its net leverage ratio below 3.0x ahead of schedule. Elanco plans to combine debt paydown with investments in innovation while implementing this multi-year share repurchase program to enhance long-term shareholder value.
Lame, suffocated and dead: The drug supersizing America’s cattle
Elanco Animal Health's drug Experior, approved by the FDA to reduce ammonia emissions in cattle, is now a major profit driver due to its off-label growth-promoting effects, despite concerns about animal welfare. The drug has been linked to increased lameness, bloat, and deaths in cattle in both studies and real-world feedlots. Critics point to the FDA's approval process and the influence of pharmaceutical companies and academia on the livestock industry, raising questions about drug safety and transparency.
Two healthcare conference chats with Elanco’s CEO will stream live.
Elanco Animal Health (NYSE: ELAN) CEO Jeff Simmons will participate in fireside chats at two upcoming investor conferences. He will speak at the 9th Annual Evercore Healthcare Conference on November 30 and the Piper Sandler 38th Annual Healthcare Conference on December 3. Live audio webcasts and replays will be available on Elanco's investor website.
Form 4 Elanco Animal Health: Robert M. VanHimbergen (EVP and CFO) For: 13 November By Investing.com
This article reports on a Form 4 filing for Elanco Animal Health, specifically detailing transactions by Robert M. VanHimbergen, the company's EVP and CFO. The filing pertains to activities that occurred on November 13. The article is a brief news alert from Investing.com, providing essential information about insider trading activity.
CEO Jeffrey N. Simmons gets a stock award payable in cash or shares at Elanco Animal Health (ELAN).
Jeffrey N. Simmons, CEO of Elanco Animal Health (ELAN), was granted 105.5612 deferred stock units on November 13, 2026. These units, valued at $26.78 per share for a total of $3,000, can be settled in cash or shares of common stock upon termination of employment or a specified future year under the Executive Deferral and Stock Match Plan. Following this award, his direct balance of deferred stock units increased to 25,847.4735 units.
Elanco Animal Health (ELAN) awards Modi stock rights at a reported $26.78 per unit.
Elanco Animal Health Inc. (ELAN) reported that Executive Vice President Rajeev A. Modi received an award of 55.1505 deferred stock units on November 13, 2026, at a price of $26.78 per unit. This transaction increased his total holdings to 10,145.0919 deferred stock units. These units represent the right to receive common stock shares or their cash equivalent upon termination of employment or in a specified future year.
T. Rowe Price reports sole voting power over 22.3M Elanco (ELAN) shares.
T. Rowe Price Investment Management, Inc. has filed an amended Schedule 13G for Elanco Animal Health Inc. (ELAN), reporting beneficial ownership of 22,379,405 shares, or 4.5% of the common stock, as of September 30, 2026. The filing explicitly states that T. Rowe Price has sole voting power over 22,307,497 shares and sole dispositive power over all 22,379,405 shares, while denying beneficial ownership. This disclosure outlines T. Rowe Price's significant influence over Elanco's stock, without admitting to beneficial ownership.
Elanco - Scratch That Vetinary Education Tour — LBB
Brand Champions partnered with Elanco to launch "Scratch That," a five-location event series that rethinks traditional veterinary education. Focused on canine atopic dermatitis, the tour combines expert-led clinical education, peer networking, and wellbeing sessions for veterinary professionals. The initiative, which kicked off on November 2, 2026, aims to provide an engaging and supportive experience beyond conventional continuing professional development.
Elanco Shares Internship Opportunities with MoWest Students at Employer Spotlight Event
Elanco Animal Health recently held an Employer Spotlight event at MoWest, inviting students, especially those in Engineering, Chemistry, Biology, and Supply Chain Management, to learn about their summer 2027 internship opportunities. The company, known for its innovative animal health solutions, is looking to fill six intern positions, emphasizing teamwork and a readiness to learn. Interns will gain hands-on experience and could potentially secure full-time employment, with applications due by November 15, 2026.
JP Morgan maintains Elanco Animal Health at Overweight, raises price target to $35 from $33
JP Morgan has maintained its "Overweight" rating for Elanco Animal Health (ELAN) and increased its price target from $33 to $35, representing a 6.1% hike. This new target suggests a potential upside of 36.0% from the stock's closing price on November 6th. Other recent analyst actions on ELAN include a "Maintains Equal-Weight" from Morgan Stanley with a $25 target, a "Downgrades Hold" from Jefferies with a $24 target, and an "Initiates Coverage On Buy" from Goldman Sachs with a $32 target.
Paws and profits: Elanco names new chief people officer, AHI welcomes government affairs VP, and more updates
Elanco Animal Health has appointed Jamie Preston, MHA, as its new executive vice president and chief people officer, effective November 3, 2026. The Animal Health Institute (AHI) announced Andrew Bailey, JD, as vice president of government affairs and public policy, starting November 16, 2026. Additionally, the University of Maryland Eastern Shore School of Veterinary Medicine (UMES SVM) has named Paul Nader, DVM, as associate professor of anatomy, ahead of its inaugural DVM class in summer 2027.
KeyBanc reiterates Elanco Animal Health stock rating on strong Q3
KeyBanc has reaffirmed its Overweight rating and $30.00 price target for Elanco Animal Health (NYSE:ELAN) shares, citing strong third-quarter results that bolster confidence in the company's 2027 outlook. The firm expects mid-single-digit organic revenue growth and further gross margin expansion driven by new product launches and strategic initiatives. Elanco also reported better-than-expected Q3 2026 earnings and revenue, leading to a raised full-year financial outlook.
KeyBanc reiterates Elanco Animal Health stock rating on strong Q3 By Investing.com
KeyBanc has reiterated an Overweight rating and a $30.00 price target for Elanco Animal Health (NYSE: ELAN) shares, citing strong third-quarter results that bolster confidence in its 2027 outlook. The company's gross margin expanded by 300 basis points year-over-year to 56.1%, and analysts anticipate mid-single-digit organic revenue growth and further gross margin expansion towards 60% driven by new product launches and strategic initiatives. Despite trading above its fair value, analysts predict profitability for the company this year.
Pet health spending remains ‘nonnegotiable’ priority, survey finds
A recent Elanco survey indicates that pet owners consider animal health spending a non-negotiable priority, even amid economic pressures, with 93% maintaining or increasing their spending. While medication purchases are shifting away from veterinary clinics to other retail channels, veterinarians' recommendations remain the primary influence on product selection. Future demand for pet ownership also appears strong, with 25% of current owners planning to adopt another pet within the next year.
Elanco Animal Health Sees Strong Momentum Heading Into 2027
Elanco Animal Health (NYSE: ELAN) reported better-than-expected third-quarter financial results, driven by strong demand and higher prices for its pet health products, particularly Zenrelia and Credelio Quattro. The company exceeded analyst estimates for both earnings and sales and raised its full-year 2026 guidance, expecting mid-single-digit organic constant currency revenue growth and low-double-digit adjusted EPS growth heading into 2027. This positive outlook is fueled by significant market share gains and increased clinic penetration for its key innovative products.
Elanco Animal Health Q3 2026 Earnings Call Transcript
Elanco Animal Health reported strong third-quarter 2026 financial results, with reported revenue up 11% and organic constant currency growth of 9%, driven by increased demand in International and U.S. Pet Health. The company achieved significant gross margin expansion, reduced net leverage below three times, and raised its full-year innovation revenue target to $1.275 billion. Elanco also reiterated its 2027 guidance for mid-single-digit revenue growth, high-single-digit adjusted EBITDA growth, and low-double-digit adjusted EPS growth, highlighting continued momentum from key product launches like Zenrelia and Credelio Quattro.
October Consumer Research Confirms Pet Health Remains Non-Negotiable Household Priority
Elanco Animal Health Incorporated (NYSE: ELAN) released findings from its latest U.S. consumer research, indicating that pet owners prioritize pet health spending despite economic pressures, with 93% maintaining or increasing spending in the last three months. The survey also revealed a shift in pet medication purchasing towards omnichannel convenience, while veterinarians remain the primary trusted authority. Additionally, the research suggests strong future demand for pet adoption.
Elanco raises 2026 outlook as Q3 revenue grows 11% to $1.265 billion
Elanco Animal Health (NYSE:ELAN) reported strong third-quarter 2026 results, with revenue up 11% to $1.265 billion and a net income of $18 million, a significant improvement from a loss in the prior year. The company saw growth across both its Pet Health and Farm Animal segments, leading it to increase its full-year 2026 revenue and adjusted EPS guidance, along with its innovation revenue target. Elanco remains focused on product innovation and operational efficiency to drive future growth.
October Consumer Research Confirms Pet Health Remains Non-Negotiable Household Priority
Elanco Animal Health (NYSE: ELAN) released consumer research indicating that 93% of surveyed pet owners maintained or increased their pet spending over the past three months, with a similar percentage expecting to do so in the year ahead. The survey, conducted in mid-October 2026, also found that only 7% of consumers would cut pet health spending under economic pressure, far less than other discretionary categories. Additionally, 38% of pet owners have shifted medication purchases outside veterinary clinics, though clinics remain the largest single channel.
Elanco Animal Health Reports Third Quarter 2026 Results
Elanco Animal Health announced strong third-quarter 2026 results, reporting revenue of $1.265 billion, an 11% increase year-over-year with 9% organic constant currency growth. The company also raised its full-year 2026 guidance for revenue, Adjusted EBITDA, and Adjusted EPS, and achieved a net leverage ratio of 2.9x Adjusted EBITDA. This performance was driven by accelerated price growth, organic revenue growth in Pet Health and Farm Animal segments, and gross margin expansion, leading to increased capital allocation flexibility.
Elanco’s (NYSE:ELAN) Q3 2026 sales beat estimates, stock soars
Elanco (NYSE: ELAN) exceeded Wall Street's Q3 2026 revenue and adjusted EPS estimates, reporting an 11.3% year-on-year revenue increase to $1.27 billion and an adjusted profit of $0.27 per share. The company also provided better-than-expected revenue guidance for Q4 2026 and raised its full-year adjusted EPS guidance. Following the announcement, Elanco's shares surged 7.4%.
Elanco Animal Health Shares Jump 7.6% as Q3 Earnings Beat Forecasts and Company Raises 2026 Outlook
Elanco Animal Health Incorporated (NYSE:ELAN) saw its shares climb 7.6% after reporting stronger-than-expected third-quarter 2026 earnings and revenue. The company's adjusted earnings of $0.27 per share and revenue of $1.26 billion both surpassed analyst estimates, driven by growth in its Pet Health and Farm Animal segments. Consequently, Elanco raised its full-year 2026 financial guidance for both adjusted earnings and revenue.
Elanco Animal Health Reports Soon: How Has The Stock Reacted To Past Earnings?
Elanco Animal Health (NYSE:ELAN) is set to release its earnings on November 6, 2026. This article analyzes the company's stock performance following past earnings reports, noting that positive one-day returns occurred 63% of the time over the last five years, rising to 75% in the last three years. It also examines correlations between one-day, five-day, and twenty-one-day post-earnings returns and considers how the earnings reactions of peers like Merck, IDEXX Laboratories, and Neogen might foreshadow Elanco's performance.
Voting power over 58.2M shares accompanies FMR's reported stake in Elanco Animal Health (ELAN).
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G/A, disclosing a 13.3% beneficial ownership in Elanco Animal Health Inc. (ELAN), totaling 66,242,260 shares. FMR LLC specifically holds sole voting power over 58,153,259 shares and sole dispositive power over all 66,242,260 shares. Abigail P. Johnson also holds sole dispositive power over the same number of shares but no sole voting power.
Elanco (ELAN) reports earnings tomorrow: what to expect
Elanco (ELAN) is set to report earnings before market hours on Friday, with analysts expecting a 6.1% year-on-year revenue growth. The company has a history of beating revenue estimates and saw a 10.2% increase last quarter, reporting $1.37 billion. Investor sentiment in the pharmaceuticals segment is positive, with Elanco's share price up 10.5% over the last month, trading below its average analyst price target of $30.23.
Elanco (ELAN) reports earnings tomorrow: what to expect
Elanco (NYSE: ELAN), an animal health company, is scheduled to report its Q3 earnings before market hours this Friday. The market anticipates a 6.1% year-on-year revenue growth, a slowdown from the 10.4% increase recorded in the same quarter last year. Analysts have largely reconfirmed their estimates, and Elanco typically meets Wall Street's revenue expectations.
Elanco - Zenrelia launch at the London Vet Show — LBB
Brand Champions created a standout exhibition space for Elanco's Zenrelia launch at the London Vet Show 2025, which aimed to attract visitors with a calm, 'zen' theme centered around a cherry blossom tree. The immersive stand generated 1,382 registrations and won the Exhibition Award at the 2026 Veterinary Marketing Association Annual Awards, with praise from both Brand Champions' CEO Fiona Wylie and Elanco's Marketing Manager Vicky Sumpter for the collaborative effort.
Elanco CFO Robert M. VanHimbergen Acquires 8.5438 Deferred Stock Units at $23.06 Each
Robert M. VanHimbergen, Executive Vice President and CFO of Elanco Animal Health Inc., acquired 8.5438 Deferred Stock Units on October 30, 2026, at a price of $23.06 per unit. This transaction, filed with the SEC on November 3, 2026, increased his direct holdings to 184.4621 units. These units will settle in cash or shares upon employment termination or during a specified future year.
Form 4 Elanco Animal Health: Rajeev A. Modi (Officer) For: 30 October
This article reports on a Form 4 filing for Elanco Animal Health (ELAN) concerning officer Rajeev A. Modi, specifically referencing activities on October 30th. Form 4 filings detail changes in beneficial ownership of company stock by insiders. The article indicates a 3.01% increase in ELAN's stock price.
Elanco Animal Health Inc Initial Statement of Beneficial Ownership
Jamie Preston, the EVP and Chief People Officer of Elanco Animal Health Inc. (ELAN), filed an Initial Statement of Beneficial Ownership of Securities (Form 3) with the SEC. The filing, dated November 3, 2026, indicates that Preston does not beneficially own any derivative or non-derivative securities of the company at the time of this initial statement.
Elanco's finance chief and pet health executive will join a live webcast Nov. 9.
Elanco Animal Health (NYSE: ELAN) announced its participation in the UBS Global Healthcare Conference on November 9, 2026. CFO Bob VanHimbergen and EVP U.S. Pet Health and Global Digital Transformation Bobby Modi will engage in a fireside chat at 1:15 p.m. EST, with a live audio webcast available on Elanco's investor website. The news, released on November 3, 2026, also noted a slight increase in ELAN's stock price and above-average trading volume on the day of the announcement.
Elanco to Participate in UBS Global Healthcare Conference
Elanco Animal Health Incorporated will attend the UBS Global Healthcare Conference on November 9, 2026. Bob VanHimbergen and Bobby Modi will participate in a fireside chat at 1:15 p.m. EST. A live audio webcast and a replay will be available on Elanco's investor website.
Form 4 Elanco Animal Health: Jeffrey N. Simmons (Director, PRESIDENT, CEO AND DIRECTOR) For: 30 October
This article reports on a Form 4 filing for Elanco Animal Health (ELAN), indicating activity by Jeffrey N. Simmons, who holds positions as Director, President, CEO, and Director. The filing pertains to transactions on October 30. The article also includes various market data and other news from Investing.com.
Elanco Animal Health Is Maintained at Equal-Weight by Morgan Stanley
Morgan Stanley has maintained its "Equal-Weight" rating for Elanco Animal Health. The decision reflects the firm's current outlook on the company's performance and market position within the animal health sector. No specific price target was mentioned in this update.
Caring for Both Ends of the Leash: Elanco and The Veterinary Cooperative Support The Street Dog Coalition
Elanco and The Veterinary Cooperative (TVC) have partnered to donate over $14,000 to The Street Dog Coalition, a nonprofit providing free veterinary care to pets of people experiencing homelessness. The donation, raised through a "Paws for a Cause: Bingo Night" and matched by Elanco, will fund care for more than 120 pets. This initiative highlights the "One Health" approach, recognizing the interconnectedness of human and animal well-being.
Elanco Animal Health (ELAN) Advances Product Pipeline, Is The Stock Still Undervalued?
Elanco Animal Health (ELAN) has appointed a new Chief People Officer and is advancing several new therapies, amidst a volatile share price performance. Despite recent gains, the stock has seen a decline over the last three months, though long-term returns are substantial. The company is considered 25% undervalued by many, with a fair value estimated at $30.31, due to its operational focus on strategic product launches and debt reduction efforts.
Europe Dog Dewormers Market Companies, Size & Trends 2026-2035
The Europe dog dewormers market is projected to grow from USD 596.40 million in 2026 to USD 1,222.34 million by 2035, at a CAGR of 8.30%. This growth is driven by rising dog ownership, increased veterinary recommendations for regular deworming, and a shift towards higher-priced monthly combination products. Germany currently dominates the market, while Poland is expected to be the fastest-growing country, fueled by increasing pet care spending and veterinary visits.
Farm Hands West: Eco Farms names Jim Leach president, Meristem selects Matthew Deyle as vice president, Elanco Animal Health appoints Jamie Preston
Eco Farms has appointed Jim Leach as its new president, effective November 16, succeeding founder Steve Taft who will retire in June 2027. Meristem Crop Performance named Matthew Deyle as vice president of business development, and Elanco Animal Health appointed Jamie Preston as executive vice president and chief people officer. Other appointments include Marie Bucko as interim CEO of the Animal Health Institute and Mae Sheaffer joining Corteva Agriscience.
Farm Hands on the Potomac: Elanco Animal Health appoints Jamie Preston EVP, Animal Health Institute names Marie Bucko interim CEO
Elanco Animal Health has appointed Jamie Preston as Executive Vice President and Chief People Officer, while Marie Bucko has been named interim CEO of the Animal Health Institute. Additionally, Kansas State University welcomed Scott Eilert as the new head of its Department of Animal Sciences and Industry. The article also details several other appointments and retirements within the agricultural and animal health sectors, including new roles at Corteva Agriscience, Voice of Milk, and the American Food Power Council.
UBS Maintains Elanco Animal Health(ELAN.US) With Buy Rating, Maintains Target Price $33
UBS has reiterated its Buy rating on Elanco Animal Health (ELAN.US), maintaining a target price of $33. This indicates a continued positive outlook from the investment bank regarding the company's stock performance.
Addressing Critical Health Needs Through Innovation
Elanco focuses on innovation in animal health by understanding needs, identifying solution gaps, and finding stronger ways to help. The company's R&D model, supported by strategic partnerships and new facilities, has led to a significant increase in blockbuster-potential projects and product launches since 2021. Elanco aims to address unmet needs across pets and livestock with solutions like Befrena™, Zenrelia™, and Credelio Quattro™.
Elanco names Jamie Preston chief people officer
Elanco Animal Health has appointed Jamie Preston as executive vice president and chief people officer, effective November 3. Preston joins Elanco from Eli Lilly and Co., bringing 23 years of experience, including nearly two decades in human resources. She succeeds Dave Kinard, who will retire at the end of the year and will assist with the transition.
Elanco Animal Health, Inc. Estimates – BIVA:ELAN
This article provides an overview of Elanco Animal Health, Inc. (ELAN) financials and analyst estimates available on TradingView. It highlights sections for income statements, balance sheets, cash flow, and valuation metrics, allowing users to compare actual results with average, high, and low estimates. The platform also offers tools for visualizing financial trends over time.
Elanco Animal Health Appoints Jamie Preston Chief People Officer
Elanco Animal Health (NYSE: ELAN) has appointed Jamie Preston as executive vice president and chief people officer, effective November 3, 2026. Preston joins Elanco after 23 years at Eli Lilly, bringing extensive experience in human resources leadership, organizational design, talent management, and digital transformation. She will succeed Dave Kinard, who is retiring at the end of 2026, and will focus on talent development, workforce modernization, employee engagement, and organizational capabilities to support Elanco's global business strategy.
Elanco Animal Health appoints Jamie Preston chief people officer
Elanco Animal Health Inc. has appointed Jamie Preston as executive vice president and chief people officer, effective November 3rd. Preston, who brings 23 years of experience from Eli Lilly & Company, will succeed Dave Kinard, who is set to retire at year-end. She will focus on attracting, developing, and retaining a global workforce, emphasizing inclusion, well-being, and purpose.
Elanco Animal Health Appoints Jamie Preston as Chief People Officer
Elanco Animal Health has appointed Jamie Preston as Executive Vice President and Chief People Officer, effective November 3rd, succeeding Dave Kinard who will retire at year-end. Preston brings 23 years of experience from Eli Lilly and Company, including nearly two decades in HR leadership roles focused on global compensation, workforce innovation, and building inclusive cultures. Her appointment aims to enhance Elanco's commitment to attracting and retaining talent, and fostering a purpose-driven workplace.
Elanco Animal Health Incorporated (ELAN) Names Jamie Preston Chief People Officer
Elanco Animal Health (ELAN) has appointed Jamie Preston as EVP and Chief People Officer, effective November 3rd. Preston, formerly of Eli Lilly, will succeed Dave Kinard, who is set to retire at year-end. This leadership refresh aims to modernize talent and workforce strategies within the company.